Viking Therapeutics Q4 Loss Widens on $153.5M R&D, Phase 3 VK2735 Set for 3Q26
Viking Therapeutics reported a fourth-quarter net loss of $1.38 per share driven by R&D expenses of $153.5 million versus $31 million a year earlier, and ended with $706 million cash on hand. Oral VK2735 will enter Phase 3 in 3Q26, a maintenance dosing study is fully enrolled, and an amylin agonist IND is expected.
1. Fourth-Quarter Financial Results
Viking Therapeutics reported a net loss of $1.38 per share for the fourth quarter as R&D expenses rose to $153.5 million from $31 million in the prior year. The company ended the period with $706 million in cash and equivalents, maintaining a strong balance sheet despite the increased spending.
2. Clinical Pipeline and Corporate Update
Viking plans to advance its oral VK2735 candidate into Phase 3 trials in 3Q26, with a fully enrolled maintenance dosing study set to generate data later in the year. Additionally, an IND filing for a novel amylin agonist is expected this quarter, highlighting continued progress in its obesity therapy portfolio.